Table 2.

Patient characteristics according to metabolic activity (SUV_max and TLG) (n = 59)

Clinical feature	SUVmax			TLG
	Total no.	Median (range)	p value	Median (range)	P value
Age			0.86		0.89
≤median	31	7.94 (0–28.21)		85.41 (0–1881.53)
>median	28	6.47 (0–26.95)		56.22 (0–834.41)
Sex			0.05		0.02
Male	43	8.28 (0–28.21)		106.81 (0–1881.53)
Female	16	5.50 (0–26.95)		17.97 (0–834.41)
Body mass index			1.00		0.39
≤median	29	7.32 (0–28.21)		86.27 (0–1881.53)
>median	30	7.50 (0–23.44)		45.62 (0–834.41)
Location of tumor			0.002		0.01
Siewert type III	29	10.96 (0–26.95)		241.80 (0–1881.53)
Distal stomach	30	5.66 (0–28.21)		27.14 (0–907.91)
Tumor differentiation			0.05		0.37
Well/moderate	18	9.88 (0–26.95)		146.97 (0–759.92)
Poor	41	6.02 (0–28.21)		54.93 (0–1881.53)
Lauren classification			0.06		0.36
Intestinal	21	9.47 (0–26.95)		135.15 (0–759.92)
Diffuse	38	5.99 (0–28.21)		55.41 (0–1881.53)
Signet ring cells			0.004		0.02
Yes	26	5.80 (0–23.31)		41.04 (0–834.41)
No	33	9.47 (0–28.21)		241.80 (0–1881.53)
Baseline T category			0.02		0.004
T1/2	5	0 (0–7.38)		0(0–16.77)
T3/T4	54	7.83 (0–28.21)		89.79 (0–1881.53)
Baseline N category			0.01		0.02
N0	25	5.56 (0–26.95)		34.64 (0–759.92)
N1/2/3	34	8.67 (0–28.21)		150.23 (0–1881.53)
Baseline clinical stage			0.01		0.004
I/IIA/IIB	24	5.35 (0–26.95)		25.40 (0–759.92)
III/IVA	35	9.05 (0–28.21)		158.79 (0–1881.53)
Response			0.009		0.21
P0	10	14.62 (0–28.21)		260.06 (0–907.91)
P1	35	6.53 (0–24.18)		54.93 (0–1881.53)
P2	14	5.78 (0–17.2)		45.62 (0–834.41)

SUV_max, maximum standardized uptake value; TLG, total lesion glycolysis; BMI, body mass index.